Janux Therapeutics, Inc. focuses on creating next-generation biologics using its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The company's pipeline primarily consists of engineered T cell engagers and bispecific antibodies that target specific tumor antigens while remaining inactive in healthy tissue. Its lead clinical candidate, JANX007, is a prostate-specific membrane antigen (PSMA)-targeted therapy evaluated for metastatic castration-resistant prostate cancer. Beyond its internal oncology and autoimmune disease programs, Janux generates revenue through strategic research and licensing collaborations with major pharmaceutical companies such as Merck and Bristol Myers Squibb.
